[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021003230A - Composiciones farmaceuticas que comprenden meloxicam. - Google Patents

Composiciones farmaceuticas que comprenden meloxicam.

Info

Publication number
MX2021003230A
MX2021003230A MX2021003230A MX2021003230A MX2021003230A MX 2021003230 A MX2021003230 A MX 2021003230A MX 2021003230 A MX2021003230 A MX 2021003230A MX 2021003230 A MX2021003230 A MX 2021003230A MX 2021003230 A MX2021003230 A MX 2021003230A
Authority
MX
Mexico
Prior art keywords
meloxicam
pharmaceutical compositions
compositions
nsaid
pharmacokinetics
Prior art date
Application number
MX2021003230A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2021003230A publication Critical patent/MX2021003230A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cosmetics (AREA)

Abstract

En la presente se describen composiciones que comprenden un AINE, tal como meloxicam en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones se pueden administrar por vía oral, por ejemplo, para mejorar la biodisponibilidad o farmacocinética del AINE para el tratamiento de afecciones, tales como el dolor.
MX2021003230A 2015-11-25 2017-08-09 Composiciones farmaceuticas que comprenden meloxicam. MX2021003230A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259993P 2015-11-25 2015-11-25

Publications (1)

Publication Number Publication Date
MX2021003230A true MX2021003230A (es) 2022-08-18

Family

ID=60389519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010304A MX2017010304A (es) 2015-11-25 2016-04-11 Composiciones farmaceuticas que comprenden meloxicam.
MX2021003230A MX2021003230A (es) 2015-11-25 2017-08-09 Composiciones farmaceuticas que comprenden meloxicam.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017010304A MX2017010304A (es) 2015-11-25 2016-04-11 Composiciones farmaceuticas que comprenden meloxicam.

Country Status (21)

Country Link
EP (2) EP4008319A1 (es)
JP (5) JP6746612B2 (es)
KR (8) KR102465027B1 (es)
CN (2) CN113144218A (es)
AU (4) AU2016218992C1 (es)
CA (3) CA3204396A1 (es)
DK (1) DK3256138T3 (es)
ES (1) ES2913288T3 (es)
HK (1) HK1243650A1 (es)
HU (1) HUE058677T2 (es)
IL (2) IL253925B (es)
LT (1) LT3256138T (es)
MX (2) MX2017010304A (es)
MY (1) MY191574A (es)
NZ (2) NZ734233A (es)
PL (1) PL3256138T3 (es)
PT (1) PT3256138T (es)
RS (1) RS63260B1 (es)
SG (2) SG11201706123XA (es)
SI (1) SI3256138T1 (es)
WO (1) WO2016131067A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US9821075B2 (en) 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
NZ734233A (en) * 2015-02-10 2018-05-25 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SI3565550T1 (sl) 2017-01-04 2021-04-30 Axsome Therapeutics, Inc. Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20240094040A (ko) * 2017-05-10 2024-06-24 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
CR20210061A (es) * 2018-07-03 2021-03-18 Axsome Therapeutics Inc Composiciones farmacéuticas que comprenden meloxicam
WO2020069138A1 (en) * 2018-09-28 2020-04-02 Axsome Therapeutics, Inc. Dosage forms comprising active pharmaceutical ingredients
SG11202107926XA (en) * 2019-02-06 2021-08-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
MX2022000968A (es) * 2019-07-26 2022-02-14 Chong Kun Dang Pharmaceutical Corp Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP7495340B2 (ja) 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
WO2022147155A1 (en) 2020-12-31 2022-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP2024517724A (ja) * 2021-04-27 2024-04-23 アニマスキュア インコーポレイテッド. オキシカム系化合物を含む筋疾患の予防または治療用組成物
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3343295A (en) 1994-08-12 1996-03-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine salt
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
JP2001513563A (ja) * 1997-08-27 2001-09-04 ヘキサル アーゲー 溶解性および生物学的利用能の改良されたメロキシカムの医薬組成物
EP1411900B2 (en) * 2001-06-01 2013-12-04 Pozen, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
GB0320382D0 (en) * 2003-08-30 2003-10-01 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Pharmaceutical compositions
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
EP1744757A4 (en) * 2004-05-04 2009-04-22 Equitech Corp IMPROVED ENHANCED COMPOSITION
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US8343995B2 (en) * 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2170828B1 (en) * 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
KR101912709B1 (ko) * 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
ES2933198T3 (es) * 2010-10-21 2023-02-02 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para usar
CN102526058A (zh) * 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
NZ734233A (en) * 2015-02-10 2018-05-25 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
NZ742220A (en) 2023-07-28
IL253925B (en) 2021-04-29
IL253925A0 (en) 2017-10-31
JP2021066749A (ja) 2021-04-30
EP3256138B1 (en) 2022-02-23
SG10202010157VA (en) 2020-11-27
MY191574A (en) 2022-06-30
KR20200117055A (ko) 2020-10-13
SG11201706123XA (en) 2017-08-30
CN113144218A (zh) 2021-07-23
KR20220110869A (ko) 2022-08-09
AU2019203328A1 (en) 2019-05-30
AU2016218992B2 (en) 2019-02-14
KR20220107313A (ko) 2022-08-02
MX2017010304A (es) 2018-06-19
LT3256138T (lt) 2022-06-10
HUE058677T2 (hu) 2022-09-28
KR102550497B1 (ko) 2023-07-03
AU2020205306A1 (en) 2020-08-06
AU2016218992C1 (en) 2019-09-26
CA2976272C (en) 2018-09-04
AU2020205306B2 (en) 2022-03-10
CN107405359A (zh) 2017-11-28
KR102163404B1 (ko) 2020-10-08
KR20230038592A (ko) 2023-03-20
JP6746612B2 (ja) 2020-08-26
WO2016131067A2 (en) 2016-08-18
KR102424013B1 (ko) 2022-07-25
CA3011562A1 (en) 2016-08-18
JP7017275B2 (ja) 2022-02-08
EP4008319A1 (en) 2022-06-08
CA3204396A1 (en) 2016-08-18
JP2022040370A (ja) 2022-03-10
AU2022203861A1 (en) 2022-06-23
CN107405359B (zh) 2021-04-20
AU2019203328B2 (en) 2020-05-28
KR102465027B1 (ko) 2022-11-09
KR20220153674A (ko) 2022-11-18
HK1243650A1 (zh) 2018-07-20
JP2019131596A (ja) 2019-08-08
JP7332202B2 (ja) 2023-08-23
WO2016131067A3 (en) 2016-10-06
CA2976272A1 (en) 2016-08-18
AU2020205306C1 (en) 2022-10-13
JP2023133545A (ja) 2023-09-22
PL3256138T3 (pl) 2022-08-01
SI3256138T1 (sl) 2022-07-29
IL281863A (en) 2021-05-31
ES2913288T3 (es) 2022-06-01
AU2016218992A1 (en) 2017-08-17
DK3256138T3 (da) 2022-05-16
KR102507663B1 (ko) 2023-03-07
KR20170126915A (ko) 2017-11-20
JP6842122B2 (ja) 2021-03-17
PT3256138T (pt) 2022-05-23
RS63260B1 (sr) 2022-06-30
AU2022203861B2 (en) 2024-09-19
JP2018508570A (ja) 2018-03-29
EP3256138A2 (en) 2017-12-20
KR102447080B1 (ko) 2022-09-23
KR20210111333A (ko) 2021-09-10
NZ734233A (en) 2018-05-25
EP3256138A4 (en) 2019-10-02
CA3011562C (en) 2023-08-29
AU2019203328C1 (en) 2020-08-27
KR20230098923A (ko) 2023-07-04
KR102429352B1 (ko) 2022-08-03

Similar Documents

Publication Publication Date Title
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2024005716A (es) Composiciones farmaceuticas que comprenden meloxicam.
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
CA2956871C (en) Compounds active towards bromodomains
MY187047A (en) Selective pyy compounds and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
GB2541571A (en) Pharmaceutical compositions
IN2013MU03583A (es)
CL2015002897A1 (es) Inhibidores de bace1
IN2013MU00711A (es)
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EP3659597A3 (en) Compositions and methods for drug sensitization of parasites
BR112017014295A2 (pt) composição farmacêutica.
IN2014MU00043A (es)
MX2016010104A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
UA106905U (uk) Фармацевтична композиція
IN2014MU00077A (es)
IN2013MU03656A (es)
IN2014CH01195A (es)
UA88138U (ru) Лекарственное средство в форме перорального раствора для лечения и профилактики ишемии тканей организма
IN2013MU03310A (es)